ALGN Align Technology, Inc.

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

Align Technology has lagged the broader market over the past year, even as Wall Street analysts remain cautiously optimistic about the company’s future prospects.

Align Technology (NASDAQ:ALGN) sees continued growth potential for Invisalign clear aligners in the United States and internationally despite a challenging consumer environment, Chief Financial Officer John Morici said during a Baird investor conference. Morici said inflation and patient reluctance

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

Align Technology expands Invisalign and digital dentistry adoption as iTero gains traction, but weak capital spending and currency volatility remain risks.

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.

Align Technology stock has delivered a steeply negative 5 year share price performance, yet current valuation checks suggest the market price may now be below what its cash flows imply. At the same time, traditional market multiples look roughly in line with peers, which leaves investors weighing an intrinsic value signal that points to a discount against a share price that does not screen as extreme on earnings based measures. Over the past 5 years, Align Technology shares have declined...

Align Technology (NasdaqGS:ALGN) appoints Quentin Blackford of iRhythm Technologies to its board of directors. Andrea L. Saia plans to resign from Align Technology's board after serving for more than a decade. The board change introduces new operating and strategy experience as Align Technology marks the end of Saia's long tenure during its growth as a digital dentistry leader. For investors tracking how leadership shifts can influence long term direction, it can be useful to compare Align...

Align Technology (ALGN) is back in focus after its latest earnings report, which met revenue expectations and exceeded earnings forecasts, while also including softer guidance amid pricing and economic pressures across the sector. Align Technology’s recent guidance weighed on sentiment, and the stock has fallen about 12% since the earnings release. This contributed to a 9.26% decline in the 30 day share price return, even though the 1 year total shareholder return of 14.03% remains positive...

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Align Technology (NASDAQ:ALGN) and its peers.

Align Technology (ALGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Despite Align Technology's weak performance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.

Align's $37.5M U.K. VAT liability, new 20% VAT charges and pending appeal add fresh earnings uncertainty amid currency and mix pressures.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Align Technology (ALGN) disclosed late Tuesday that the Jinan Intermediate People's Court in China i

Clear aligner volumes hit record levels amid $37.5 million UK VAT liability.

Dental technology company Align Technology (NASDAQ:ALGN) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 4.3% year on year to $1.06 billion. On the other hand, next quarter’s revenue guidance of $1.01 billion was less impressive, coming in 1.3% below analysts’ estimates. Its non-GAAP profit of $2.64 per share was 1.7% above analysts’ consensus estimates.

What the latest guidance and Q2 results tell you about Align Technology Align Technology (ALGN) just paired record second quarter revenue with updated 2026 guidance, giving you fresh data on how its clear aligner business, margins, and cash returns to shareholders are evolving. The company reported second quarter 2026 sales of US$1.06b, with clear aligner volumes supporting that performance while systems and services saw softer demand. Net income for the quarter was US$108.29m, and diluted...

Align Technology shares rise after Q2 earnings and revenues beat estimates, fueled by record Clear Aligner shipments and wider non-GAAP margins.

ALGN highlights record clear aligner volumes, digital workflow expansion and margin gains while balancing scanner pricing pressures and long-term growth plans.

Moby summary of Align Technology, Inc.'s Q2 2026 earnings call

Align Technology Inc (ALGN) posts record Q2 2026 revenue of $1.06 billion, driven by strong Clear Aligner volume growth, while navigating a sluggish North American retail market and a UK VAT ruling.

Align Technology (NASDAQ:ALGN) reported record second-quarter revenue of $1.06 billion, up 4.3% from a year earlier, as record clear aligner volumes and higher revenue in that business offset continued weakness in its systems and services segment. Chief Executive Officer Joe Hogan said second-quart

While the top- and bottom-line numbers for Align Technology (ALGN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Align Technology (ALGN) delivered earnings and revenue surprises of +3.13% and +0.43%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

July 29 (Reuters) - Align Technology said on Wednesday it will add three new independent directors to its board and launch a review of its operations, following talks with activist investor Elliott

Align Technology will add three new independent directors to its board and launch a review of its operations ‌following talks with activist investor Elliott Investment Management, the company said ‌on Wednesday. The three new board ​members, who have not yet been named, will be chosen for their expertise in healthcare technology, medical devices, global operations, and scaling high-growth businesses. Elliott, one of Wall Street's most prominent activist investors, has increasingly turned its attention to ‌healthcare companies over the past ⁠year, often pushing for board representation and strategic reviews to boost performance.

Dental technology company Align Technology (NASDAQ:ALGN) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 4.3% year on year to $1.06 billion. On the other hand, next quarter’s revenue guidance of $1.01 billion was less impressive, coming in 1.3% below analysts’ estimates. Its non-GAAP profit of $2.64 per share was 1.7% above analysts’ consensus estimates.

Dental technology company Align Technology (NASDAQ:ALGN) will be announcing earnings results this Wednesday after the bell. Here’s what to look for.

ALGN's global expansion and iTero innovations support growth, but can they offset currency headwinds and macro pressures?

ALGN reports Q2 results on July 29, with investors watching Clear Aligner growth as higher volumes and digital offerings shape quarterly performance.

While the market frets about near-term headwinds, the consulting giant is quietly deploying billions to buy its next wave of growth.

Cheniere Energy (NYSE:LNG) has appointed Britt Vitalone, a veteran finance leader with experience at McKesson and Align Technology, to its Board of Directors. Vitalone will serve on both the Audit and Compensation Committees, adding expertise in corporate finance, capital allocation, and governance. The company has also adjusted several revolving credit facilities, including higher commitments, extended maturities, and updated terms for subsidiary credit lines. These governance and credit...

Myriad Genetics expands its testing portfolio and advances its Cancer Care Continuum strategy. Can reimbursement risks and cost pressures temper growth?

ALGN vs. SAUHY: Which Stock Is the Better Value Option?